In the published article, there was an error in the legend for Figure 1 and Figure 3 as published, regarding the light green zone for 95% prediction intervals. The corrected legends appear below.
Figure 1
Trial-level correlation between hazard ratios for OS and PFS/TTP in phase III RCTs. Green circles represent trials with a size proportional to the number of patients, blue line for the estimated regression line and the light green zone for 95% confidence intervals. OS, overall survival; PFS/TTP, progression free survival/time to progression; RCTs, randomized controlled trials.
Figure 3
Treatment arm-level correlation between 5-year OS and 1-year PFS/TTP (A), 2-year PFS/TTP (B), 3-year PFS/TTP (C), 4-year PFS/TTP (D), 5-year PFS/TTP (E) in phase III RCTs. Green circles represent treatment arms with a size proportional to the number of patients, blue lines for the estimated regression lines and the light green zones for 95% confidence intervals. OS, overall survival; PFS/TTP, progression free survival/time to progression; RCTs, randomized controlled trials.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
Limited-stage small-cell lung cancer, surrogate endpoint, overall survival, progression-free survival, time to progression, chemoradiotherapy
Citation
Yang Y, Wang J, Wang W, Zhang T, Zhao J, Wang Y, Li Y, Wang L and Bi N (2022) Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis. Front. Oncol. 12:1007862. doi: 10.3389/fonc.2022.1007862
Received
31 July 2022
Accepted
01 August 2022
Published
24 August 2022
Volume
12 - 2022
Edited and reviewed by
Kristin Higgins, Winship Cancer Institute, Emory University, United States
Updates
Copyright
© 2022 Yang, Wang, Wang, Zhang, Zhao, Wang, Li, Wang and Bi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nan Bi, binan_email@163.com
†These authors have contributed equally to this work
This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.